Cargando…

Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits

BACKGROUND: Secondary hyperparathyroidism (SHPT) is a common complication in patients with end-stage renal disease and it is also common in hemodialysis patients. SHPT can increase bone fragility and calcification of blood vessels and soft tissues, which greatly increases the risk of death. AIM: To...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xiu, Zhao, Feng, Pan, Wei-Juan, Di, Jia-Mei, Xie, Wei-Nan, Yuan, Ling, Liu, Zhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Clinical Trials Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638032/ https://www.ncbi.nlm.nih.gov/pubmed/34904087 http://dx.doi.org/10.12998/wjcc.v9.i33.10172

Ejemplares similares

Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol
por: Hansen, Ditte, et al.
Publicado: (2009)

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
por: Cruzado, Josep M., et al.
Publicado: (2017)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

Efficacy of microwave ablation for severe secondary hyperparathyroidism in subjects undergoing hemodialysis
por: Diao, Zongli, et al.
Publicado: (2016)

Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients
por: Zheng, Jing-Quan, et al.
Publicado: (2016)

Asymmetric Dimethylarginine (ADMA) Levels Are Lower in Hemodialysis Patients Treated With Paricalcitol
por: Oliva-Damaso, Elena, et al.
Publicado: (2016)

Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism
por: Behets, Geert J, et al.
Publicado: (2015)

Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Otsuka, Keiichi, et al.
Publicado: (2018)

Impact of parathyroidectomy among nondiabetic hemodialysis patients with severe hyperparathyroidism
por: Huang, Qing-xiu, et al.
Publicado: (2022)

Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis
por: Liu, Yang, et al.
Publicado: (2019)

The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism
por: Susantitaphong, Paweena, et al.
Publicado: (2019)

Effectiveness and Safety of Ultrasound-Guided Local Paricalcitol Injection in Treating Secondary Hyperparathyroidism in ESRD: A Retrospective Study
por: Xie, Shuqin, et al.
Publicado: (2022)

Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease
por: Han, Tianzhao, et al.
Publicado: (2013)

Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Ponce, Daniela, et al.
Publicado: (2023)

Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study
por: Ketteler, Markus, et al.
Publicado: (2012)

Successful use of low-dose intravenous paricalcitol in the treatment of severe secondary hyperparathyroidism in a haemodialysis patient
por: Cozzolino, Mario, et al.
Publicado: (2008)

Value of contrast-enhanced ultrasonography in radiofrequency ablation of secondary hyperparathyroidism
por: Qin, Xiachuan, et al.
Publicado: (2021)

Cost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Cardoso, Marilia Mastrocolla de Almeida, et al.
Publicado: (2022)

Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients
por: Izquierdo, María Jesús, et al.
Publicado: (2012)

Clinical Benefits of an Adherence Monitoring Program in the Management of Secondary Hyperparathyroidism with Cinacalcet: Results of a Prospective Randomized Controlled Study
por: Forni Ogna, Valentina, et al.
Publicado: (2013)

A single-center experience of parathyroidectomy in 1500 cases for secondary hyperparathyroidism: a retrospective study
por: Zhao, Shasha, et al.
Publicado: (2022)

Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Cunningham, John, et al.
Publicado: (2019)

Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics
por: Arenas Jimenez, María Dolores, et al.
Publicado: (2021)

Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2013)

Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis
por: Zhang, Zhuolin, et al.
Publicado: (2021)

Comparison of microwave ablation treatments in patients with renal secondary and primary hyperparathyroidism
por: Ma, Haoyang, et al.
Publicado: (2020)

Erratum to: Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2014)

Effects of early enteral nutrition on Th17/Treg cells and IL-23/IL-17 in septic patients
por: Sun, Jia-Kui, et al.
Publicado: (2019)

Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism
por: Ni, Zhaohui, et al.
Publicado: (2023)

Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials
por: Xie, Yifeng, et al.
Publicado: (2017)

Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
por: Hauber, Brett, et al.
Publicado: (2017)

Evaluation of laboratory parameters and symptoms after parathyroidectomy in dialysis patients with secondary hyperparathyroidism
por: Zhang, Yi, et al.
Publicado: (2019)

Efficacy and outcome of extensive intraoperative peritoneal lavage plus surgery vs surgery alone with advanced gastric cancer patients
por: Song, En-Dong, et al.
Publicado: (2023)

A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism
por: Yokoyama, Keitaro, et al.
Publicado: (2017)

Effectiveness and safety of human umbilical cord-mesenchymal stem cells for treating type 2 diabetes mellitus
por: Lian, Xiao-Fen, et al.
Publicado: (2022)

Pin1 and secondary hyperparathyroidism of chronic kidney disease: gene polymorphisms and protein levels
por: Zhao, Yu, et al.
Publicado: (2016)

Incidence of and risk factors for post-parathyroidectomy hungry bone syndrome in patients with secondary hyperparathyroidism
por: Kritmetapak, Kittrawee, et al.
Publicado: (2020)

Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study—A Comparison
por: Zawierucha, Jacek, et al.
Publicado: (2019)

Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis
por: Franchi, Matteo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_17a2lg15v1l6q201tonlvemnn5